StockGuru Spotlight on Soligenix, Inc.
(Symbol: SNGX)
Help us update information on this company. Email any updates to: [email protected]
About Soligenix, Inc.:
Soligenix, Inc. is a development stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccinesbiodefense segment to develop vaccines and therapeutics for military and civilian applications.
Where it is located:
29 Emmons Drive
Suite C-10
Princeton, NJ
8540
United States
Key Executive Contact:
Joseph M. Warusz
Vice President, Acting CFO, Principal Acct. Officer
Ninety Day Volume:
31144 (as of date of publication)
Ninety Day Dollar Volume:
$63,503
Share Information:
20078310 shares as of 2014-08-07
Corporate Information:
State Incorporated: DE
Country Incorporated: USA
Contact, Website and Social Media for Soligenix, Inc.:
Shown Where Available
Website: http://www.soligenix.com
Facebook:
Twitter:
LinkedIn:
Telephone: (609) 538-8200
Email:
Investor Relations for Soligenix, Inc.: